Synergistic effects of quercetin and regular exercise on the recovery of spatial memory and reduction of parameters of oxidative stress in an animal model of Alzheimer's disease

Molaei, Amin; Hatami, H.; Dehghan, Gholamreza; Sadeghian, Reihaneh; Khajehnasiri, Nazli

doi:10.17179/excli2019-2082

Cited by 13 publications

(6 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported, the phenolic and avonoid compounds present in S. minor extract contribute to its antioxidant and neuroprotective functions (Akbari et al 2019;Cirovic et al 2020). In this regard, various phenolic compounds, including quercetin and ellagic acid, were observed to alleviate cognitive de cits in the experimental models (Dornelles et al 2020;Molaei et al 2020). Different bioactive components were also identi ed in S. mninor extract, including quercetin, myricetin, kaempferol, ellagic acid, catechin, gallic acid, and their derivatives.…”

Section: Discussionmentioning

confidence: 55%

Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase

et al. 2022

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 55%

Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase

et al. 2022

View full text Add to dashboard Cite

“…Another possible mechanism of effects STZ on LTP is the inhibition of lipid peroxidation in post-synaptic neurons in the hippocampus. Changes in the membrane composition of post-synaptic, including NMDA receptors and abnormal or excess signals of NMDA receptors, may have a long-lasting negative influence over LTP induced ( Molaei et al, 2020 ). Oxidative stress passively modulates synaptic formation and leads to impairment of synaptic plasticity, such as the induction of hippocampal LTP or facilitating paired pulls in the CA1 region.…”

Section: Discussionmentioning

confidence: 99%

Pre- and post-treatment of α-Tocopherol on cognitive, synaptic plasticity, and mitochondrial disorders of the hippocampus in icv-streptozotocin-induced sporadic Alzheimer’s-like disease in male Wistar rat

et al. 2023

View full text Add to dashboard Cite

ObjectiveMost dementia cases in the elderly are caused by Alzheimer’s disease (AD), a complex, progressive neurological disease. Intracerebroventricular (ICV) administration of streptozotocin (STZ) in rat’s results in aberrant brain insulin signaling, oxidative stress, and mitochondrial dysfunction that impair cognition change neural plasticity, and eventually lead to neuronal death. The current study aims to define the neuroprotective action of alpha-tocopherol in enhancing mitochondrial function and the function of synapses in memory-impaired rats brought on by icv-STZ.MethodsMale Wistar rats were pre-treated with (α-Tocopherol 150 mg/kg) orally once daily for 7 days before and 14 days after being bilaterally injected with icv-STZ (3 mg/kg), while sham group rats received the same volume of STZ solvent. After 2 weeks of icv-STZ infusion, rats were tested for cognitive performance using a behaviors test and then were prepared electrophysiology recordings or sacrificed for biochemical and histopathological assays.ResultsThe cognitive impairment was significantly minimized in the behavioral paradigms for those who had taken α-Tocopherol. In the hippocampus of icv-STZ rat brains, α-Tocopherol ocopherol effectively prevented the loss of glutathione levels and superoxide dismutase enzyme activity, lowered mitochondrial ROS and mitochondrial membrane potential, and also brought about a decrease in Aβ aggregation and neuronal death.ConclusionOur findings demonstrated that by lowering neurobehavioral impairments caused by icv-STZ, oxidative stress, and mitochondrial dysfunction, α-Tocopherol enhanced intracellular calcium homeostasis and corrected neurodegenerative defects in the brain. These findings examine the available approach for delaying AD connected to mitochondrial malfunction and plasticity issues.

show abstract

“…Further, studies have also reported the MAO-B and COMT inhibitory potential of quercetin in the PD rat model (Larit et al, 2018;Singh et al, 2003). Similarly, in mouse and rat models of AD, quercetin is reported to show AChE and Aβ inhibitory potential, ameliorate oxidative stress and neuroinflammation, suppress tau hyperphosphorylation and improve memory and cognition and oxidative stress making it a favourable candidate for AD therapy ( Álvarez- Molaei et al, 2020;Olayinka et al, 2022;Paula et al, 2019). However, quercetin is reported to possess low bioavailability and exert toxic effects at higher intake (Batiha et al, 2020;D'Andrea, 2015;Jain et al, 2013), while other studies reported that this molecule is well tolerated and exerts no toxicity (Cunningham et al, 2022).…”

Section: Plant-derived Flavonoidsmentioning

confidence: 99%

“…The effective dose of quercetin is reported to be within 30-80 mg/kg i.p. (Haleagrahara et al, 2011;Lin et al, 2022;Molaei et al, 2020) and 30-100 mg/kg orally (Paula et al, 2019;Wang, Han, et al, 2021). Quercetin administration is reported to ameliorate oxidative stress, mitochondrial dysfunction, α-synuclein aggregation and dopaminergic neuron loss in the cell as well as mice and rat models of PD along with improving motor behaviour deficits in the latter (Ahn & Jeon, 2015;Haleagrahara et al, 2011;Lin et al, 2022;Wang, Han, et al, 2021).…”

Section: Plant-derived Flavonoidsmentioning

confidence: 99%

Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

Phukan,

Roy,

Gahatraj

et al. 2023

Phytotherapy Research

View full text Add to dashboard Cite

Leading neurodegenerative diseases Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by the impairment of memory and motor functions, respectively. Despite several breakthroughs, there exists a lack of disease‐modifying treatment strategies for these diseases, as the available drugs provide symptomatic relief and bring along side effects. Bioactive compounds are reported to bear neuroprotective properties with minimal toxicity, however, a detailed elucidation of their modes of neuroprotection is lacking. The review elucidates the neuroprotective mechanism(s) of some of the major phyto‐compounds in pre‐clinical and clinical studies of AD and PD to understand their potential in combating these diseases. Curcumin, eugenol, resveratrol, baicalein, sesamol and so on have proved efficient in countering the pathological hallmarks of AD and PD. Curcumin, resveratrol, caffeine and so on have reached the clinical phases of these diseases, while aromadendrin, delphinidin, cyanidin and xanthohumol are yet to be extensively explored in pre‐clinical phases. The review highlights the need for extensive investigation of these compounds in the clinical stages of these diseases so as to utilize their disease‐modifying abilities in the real field of treatment. Moreover, poor pharmacokinetic properties of natural compounds are constraints to their therapeutic yields and this review suggests a plausible contribution of nanotechnology in overcoming these limitations.

show abstract

Synergistic effects of quercetin and regular exercise on the recovery of spatial memory and reduction of parameters of oxidative stress in an animal model of Alzheimer's disease

Cited by 13 publications

References 55 publications

Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase

Effect of Sanguisorba minor on scopolamine-induced memory loss in rat: involvement of oxidative stress and acetylcholinesterase

Pre- and post-treatment of α-Tocopherol on cognitive, synaptic plasticity, and mitochondrial disorders of the hippocampus in icv-streptozotocin-induced sporadic Alzheimer’s-like disease in male Wistar rat

Therapeutic considerations of bioactive compounds in Alzheimer's disease and Parkinson's disease: Dissecting the molecular pathways

Contact Info

Product

Resources

About